Micro-RNA in bone inhibition: A critical scoping review

Q3 Medicine
Arif Tri Prasetyo , Lisa Y. Hasibuan , Ronny Lesmana , David K. Chong , Bejo Ropii , Dany Hilmanto
{"title":"Micro-RNA in bone inhibition: A critical scoping review","authors":"Arif Tri Prasetyo ,&nbsp;Lisa Y. Hasibuan ,&nbsp;Ronny Lesmana ,&nbsp;David K. Chong ,&nbsp;Bejo Ropii ,&nbsp;Dany Hilmanto","doi":"10.1016/j.endmts.2026.100313","DOIUrl":null,"url":null,"abstract":"<div><div>Bone formation is governed by a complex regulatory network in which osteoblast differentiation and activity are tightly controlled by transcriptional, epigenetic, metabolic, and mechanical cues. Among these regulatory layers, microRNAs (miRNAs) have emerged as critical post-transcriptional modulators that fine-tune osteogenic signaling. Increasing evidence demonstrates that a distinct subset of miRNAs functions as potent endogenous inhibitors of bone formation by directly targeting essential osteogenic genes, including RUNX2, ATF4, SMADs, β-catenin, BMP receptors, and mitochondrial regulators, and by converging on pathways such as Wnt/β-catenin, BMP/Smad, TGF-β, mechanotransduction, and mitochondrial homeostasis. Furthermore, inhibitory miRNAs operate not only within osteoblast lineage cells but also through intercellular communication, particularly via osteoclast- and MSC-derived exosomes that transfer anti-osteogenic miRNAs to recipient cells, thereby coupling resorption to suppressed bone formation. This article curates miRNAs that act as bone-formation inhibitors, providing a reference of their targets, pathways, and outcomes, and highlights their potential translational utility as therapeutic agents in conditions where suppression of bone formation is desirable, such as heterotopic ossification, fibrodysplasia ossificans progressiva, and pathological bone overgrowth.</div></div>","PeriodicalId":34427,"journal":{"name":"Endocrine and Metabolic Science","volume":"21 ","pages":"Article 100313"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine and Metabolic Science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666396126000257","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Bone formation is governed by a complex regulatory network in which osteoblast differentiation and activity are tightly controlled by transcriptional, epigenetic, metabolic, and mechanical cues. Among these regulatory layers, microRNAs (miRNAs) have emerged as critical post-transcriptional modulators that fine-tune osteogenic signaling. Increasing evidence demonstrates that a distinct subset of miRNAs functions as potent endogenous inhibitors of bone formation by directly targeting essential osteogenic genes, including RUNX2, ATF4, SMADs, β-catenin, BMP receptors, and mitochondrial regulators, and by converging on pathways such as Wnt/β-catenin, BMP/Smad, TGF-β, mechanotransduction, and mitochondrial homeostasis. Furthermore, inhibitory miRNAs operate not only within osteoblast lineage cells but also through intercellular communication, particularly via osteoclast- and MSC-derived exosomes that transfer anti-osteogenic miRNAs to recipient cells, thereby coupling resorption to suppressed bone formation. This article curates miRNAs that act as bone-formation inhibitors, providing a reference of their targets, pathways, and outcomes, and highlights their potential translational utility as therapeutic agents in conditions where suppression of bone formation is desirable, such as heterotopic ossification, fibrodysplasia ossificans progressiva, and pathological bone overgrowth.
骨抑制中的微rna:一个重要的范围综述
骨形成是由一个复杂的调控网络控制的,其中成骨细胞的分化和活性受到转录、表观遗传、代谢和机械因素的严格控制。在这些调控层中,microRNAs (miRNAs)已成为调控成骨信号的关键转录后调节剂。越来越多的证据表明,mirna的一个独特的亚群通过直接靶向必要的成骨基因,包括RUNX2、ATF4、SMADs、β-catenin、BMP受体和线粒体调节因子,并通过聚集在Wnt/β-catenin、BMP/Smad、TGF-β、机械转导和线粒体稳态等途径上,作为骨形成的有效内源性抑制剂。此外,抑制性mirna不仅在成骨细胞谱系中起作用,而且还通过细胞间通信,特别是通过破骨细胞和msc衍生的外泌体将抗成骨mirna转移到受体细胞,从而将吸收与抑制骨形成结合起来。本文介绍了作为骨形成抑制剂的mirna,提供了它们的靶点、途径和结果的参考,并强调了它们作为治疗药物在抑制骨形成的条件下的潜在转化作用,如异位骨化、进行性骨化纤维发育不良和病理性骨过度生长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrine and Metabolic Science
Endocrine and Metabolic Science Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.80
自引率
0.00%
发文量
4
审稿时长
84 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书